PURPOSE: To determine the site of relapse when biochemical failure (BF) occurs after iodine-125 seed implantation for prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
MATERIALS AND METHODS: From 2001-2009, 500 men underwent implantation in Wellington, New Zealand. Men who sustained BF were placed on relapse guidelines that delayed restaging and intervention until the prostate-specific antigen (PSA) was ⩾20ng/mL.
RESULTS: Most implants (86%) had a prostate D90 of ⩾90%, and multivariate analysis showed that this parameter was not a variable that affected the risk of BF. Of 21 BFs that occurred, the site of failure was discovered to be local in one case and distant in nine cases. Restaging failed to identify the site of relapse in two cases. In nine cases the trigger for restaging had not been reached.
CONCLUSIONS: If post-implant dosimetry is generally within the optimal range, distant rather than local failure appears to be the main cause of BF. Hormone treatment is therefore the most commonly indicated secondary treatment intervention (STI). Delaying the start of STI prevents the unnecessary treatment of men who undergo PSA 'bounce' and have PSA dynamics initially mimicking those of BF.
Lamb DS, Greig L, Russell GL, Nacey JN, Broome K, Studd R, Delahunt B, Iupati D, Jain M, Rooney C, Murray J, Lamb PJ, Bethwaite PB. Are you the author?
Prostate Cancer Trials Unit, Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand; Radiation Oncology, Southern Cross Hospital, Wellington, New Zealand; Medical Physics, Southern Cross Hospital, Wellington, New Zealand; Urology, Southern Cross Hospital, Wellington, New Zealand; Omahu Urology Clinic, Hawkes Bay, New Zealand; Anesthetics, Southern Cross Hospital, Wellington, New Zealand.
Reference: Radiother Oncol. 2014 Jul 28. pii: S0167-8140(14)00292-8.